Compare MTRN & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRN | LQDA |
|---|---|---|
| Founded | 1931 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.0B |
| IPO Year | 2000 | 2020 |
| Metric | MTRN | LQDA |
|---|---|---|
| Price | $203.93 | $57.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $264.50 | $63.88 |
| AVG Volume (30 Days) | 205.2K | ★ 3.1M |
| Earning Date | 11-04-2026 | 11-10-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | ★ 1178.57 | 51.81 |
| EPS | ★ 4.57 | N/A |
| Revenue | N/A | ★ $158,320,000.00 |
| Revenue This Year | $33.41 | $379.72 |
| Revenue Next Year | $9.16 | $17.90 |
| P/E Ratio | $45.41 | ★ N/A |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $110.69 | $22.31 |
| 52 Week High | $324.99 | $93.61 |
| Indicator | MTRN | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 41.36 | 67.76 |
| Support Level | $191.03 | $53.06 |
| Resistance Level | $215.62 | $63.46 |
| Average True Range (ATR) | 13.56 | 3.42 |
| MACD | 0.07 | 2.35 |
| Stochastic Oscillator | 42.05 | 91.35 |
Materion Corp offers products that include precious and non-precious specialty metals, inorganic chemicals and powders, specialty coatings, specialty engineered beryllium and copper-based alloys, beryllium composites, ceramics, and engineered clad and plated metal systems. Its segments are: Performance Materials provides beryllium and non-beryllium containing alloy systems and custom engineered parts. Electronic Materials produces chemicals, microelectronics packaging, and specialty metal products, including vapor deposition targets and preforms. Precision Optics produces thin film coatings and optical filter materials. The Other reportable segment includes unallocated corporate costs and assets. It operates in the United States, Asia, Europe, and other countries.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.